Examples of 'empagliflozin' in a sentence
Meaning of "empagliflozin"
Empagliflozin is a drug that is used to help lower blood sugar levels in adults with type 2 diabetes
Show more definitions
- An orally available competitive inhibitor of sodium–glucose co-transporter 2 (SGLT2; SLC5A2) with antihyperglycemic activity.
How to use "empagliflozin" in a sentence
Basic
Advanced
empagliflozin
The active substances are empagliflozin and metformin.
Empagliflozin comes with a patient information leaflet.
The active substances are empagliflozin and linagliptin.
Empagliflozin should be discontinued when eGFR is persistently below.
Jardiance contains the active substance empagliflozin.
The removal of empagliflozin by haemodialysis has not been studied.
No data in humans are available on excretion of empagliflozin into milk.
Effects of empagliflozin on other medicinal products.
Identified adverse reactions of empagliflozin monotherapy.
Empagliflozin as add on to multiple daily insulin.
It contains the active substances empagliflozin and metformin.
Empagliflozin in patients inadequately controlled on metformin and linagliptin.
In patients tolerating empagliflozin whose eGFR falls persistently below.
Empagliflozin exposure is increased in patients with severe hepatic impairment.
It is a combination of empagliflozin and linagliptin.
See also
Empagliflozin administered during the period of organogenesis was not teratogenic.
The active substance is empagliflozin.
Systemic exposure of empagliflozin increased in a dose proportional manner.
Available toxicological data in animals have shown excretion of empagliflozin in milk.
Empagliflozin as add on to basal insulin.
There are no data from the use of empagliflozin in pregnant women.
Empagliflozin is mainly excreted unchanged.
It is not known whether empagliflozin passes into human breast milk.
Empagliflozin did not increase the incidence of tumours in female mice at doses up to.
The overall safety profile of empagliflozin was consistent with previous trials.
Empagliflozin increased urine glucose excretion leading to an increase in urine volume.
Jardiance is a diabetes medicine that contains the active substance empagliflozin.
Empagliflozin is not genotoxic.
Cases of hepatic injury have been reported with empagliflozin in clinical trials.
Empagliflozin and metformin.
For patients switching from separate tablets of empagliflozin and metformin.
Empagliflozin twice daily versus once daily as add on to metformin therapy.
In patients who are already taking metformin and empagliflozin as separate tablets.
Empagliflozin contains tetrahydrofuran ring but not canagliflozin nor dapagliflozin.
In vitro assessment of empagliflozin.
Empagliflozin is not recommended.
No data in humans are available on excretion of empagliflozin and linagliptin into milk.
Empagliflozin causes moderate reductions in blood pressure and body weight.
Hypoglycaemia with empagliflozin.
Empagliflozin improves both fasting and post prandial plasma glucose levels.
A causal relationship between empagliflozin and hepatic injury has not been established.
When already being treated with the free combination of empagliflozin and linagliptin.
Temporary interruption of empagliflozin should be considered in patients with complicated urinary tract infections.
Available animal data have shown excretion of empagliflozin and metformin in milk.
Treatment with empagliflozin provided reductions in seated SBP and DBP.
The overall incidence of adverse events in patients treated with empagliflozin was similar to placebo.
The safety and efficacy of empagliflozin in children and adolescents has not yet been established.
The frequencies have been comparable to those reported from the empagliflozin clinical trials.
Temporary interruption of treatment with empagliflozin should be considered until the fluid loss is corrected.
Synjardy is a diabetes medicine that contains two active substances called empagliflozin and metformin.
